AMLX - Amylyx Pharmaceuticals, Inc. Stock Price, Fair Value and News

$7.67+0.28 (+3.79%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

AMLX Price Action

Last 7 days

21.8%

Last 30 days

41.5%

Last 90 days

110.1%

Trailing 12 Months

236.4%

AMLX RSI Chart

AMLX Valuation

Market Cap

683.7M

Price/Earnings (Trailing)

-3.12

Price/Sales (Trailing)

7.83

EV/EBITDA

-2.85

Price/Free Cashflow

-3.3

AMLX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

AMLX Fundamentals

AMLX Revenue

Revenue (TTM)

87.4M

Rev. Growth (Yr)

-99.59%

Rev. Growth (Qtr)

-99.07%

AMLX Earnings

Earnings (TTM)

-218.9M

Earnings Growth (Yr)

69.77%

Earnings Growth (Qtr)

4.37%

AMLX Profitability

EBT Margin

-251.22%

Return on Equity

-108.66%

Return on Assets

-99.63%

Free Cashflow Yield

-30.29%

AMLX Investor Care

Shares Dilution (1Y)

31.08%

Diluted EPS (TTM)

-3.1

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	0	0	0	0
2024	398.0M	294.5M	190.9M	87.4M
2023	111.9M	201.5M	291.1M	380.8M
2022	0	0	11.3M	22.2M
2021	0	0	0	285.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Joshua B. Cohen
WEBSITE	https://amylyx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	338

Amylyx Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for Amylyx Pharmaceuticals, Inc.? What does AMLX stand for in stocks?

AMLX is the stock ticker symbol of Amylyx Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Amylyx Pharmaceuticals, Inc. (AMLX)?

As of Fri Jul 11 2025, market cap of Amylyx Pharmaceuticals, Inc. is 683.71 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AMLX stock?

You can check AMLX's fair value in chart for subscribers.

Is Amylyx Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether AMLX is over valued or under valued. Whether Amylyx Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Amylyx Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMLX.

What is Amylyx Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 11 2025, AMLX's PE ratio (Price to Earnings) is -3.12 and Price to Sales (PS) ratio is 7.83. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AMLX PE ratio will change depending on the future growth rate expectations of investors.